PT - JOURNAL ARTICLE AU - Gupta, Akshita AU - Konnova, Angelina AU - Smet, Mathias AU - Berkell, Matilda AU - Savoldi, Alessia AU - Morra, Matteo AU - Van averbeke, Vincent AU - De Winter, Fien AU - Peserico, Denise AU - Danese, Elisa AU - Hotterbeekx, An AU - Righi, Elda AU - , AU - De Nardo, Pasquale AU - Tacconelli, Evelina AU - Kumar, Surbhi Malhotra AU - Singh, Samir Kumar TI - Host immunological responses facilitate development of SARS-CoV-2 mutations in patients receiving monoclonal antibody treatments AID - 10.1101/2022.09.20.22280135 DP - 2022 Jan 01 TA - medRxiv PG - 2022.09.20.22280135 4099 - http://medrxiv.org/content/early/2022/10/05/2022.09.20.22280135.short 4100 - http://medrxiv.org/content/early/2022/10/05/2022.09.20.22280135.full AB - The role of host immunity in emergence of evasive SARS-CoV-2 Spike mutations under therapeutic monoclonal antibody (mAb) pressure remains to be explored. Here, we show that patients treated with various anti-SARS-CoV-2 mAb regimens develop evasive Spike mutations with remarkable speed and high specificity to the targeted mAb-binding sites. Mutations develop more frequently in immunocompromised patients and strongly correlate not only with the neutralizing capacity of the therapeutic mAbs, but also with an anti-inflammatory and healing-promoting host milieu. Machine-learning models based on soluble host-derived biomarkers identified patients at high risk of developing escape mutations against therapeutic mAbs with high accuracy. While our data demonstrate that host-driven immune and non-immune responses are essential for development of mutant SARS-CoV-2, these data could also support point-of-care decision making in reducing the risk of mAb treatment failure and improving mitigation strategies for possible dissemination of escape SARS-CoV-2 mutants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the ORCHESTRA project, which has received funding from the European Union Horizon 2020 research and innovation program under grant agreement No 101016167.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this study was obtained from the University Hospital Verona Ethic Board (protocol number: 19293) and conducted in accordance with the Declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData supporting the findings of this study are available within Supplementary Information files. SARS-CoV-2 genome sequences obtained in the project were submitted to GISAID. Trimmed read data generated and used for identification of emerging de novo Spike RBD mutants in this study have been submitted to the European Nucleotide Archive (ENA) under the project accession PRJEB55794. All other data generated in this study are available from the corresponding author upon request.